RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BUSCEMA J
Collezione AO Ordine Mauriziano

Items : 3

A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". in Future oncology (London, England) / Future Oncol. 2025 Jan;21(2):151-168. doi: 10.2217/fon-2023-0940. Epub 2024 Jul 11.

2025
AO Ordine Mauriziano

Mirza MR; Chase DM; Slomovitz BM; Christensen RD; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; et alii...

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. in Gynecologic oncology / Gynecol Oncol. 2024 Jun;185:202-211. doi: 10.1016/j.ygyno.2024.05.016. Epub 2024 Jun 3.

2024
AO Ordine Mauriziano

Makker V; Perez-Fidalgo JA; Valabrega G; Hamilton E; Van Gorp T; Sehouli J; Reginá?ová K; Richardson DL; Perri T; Oza AM; Miller DS; Alía EMG; De Giorgi U; Henry S; Spitz DL; Wimberger P; Bedna?íková M; Chon HS; Martínez-Garcia J; Pisano C; Berek JS; Romero I; Scambia G; Fariñas-Madrid L; Buscema J; Schochter F; Li K; Kalyanapu P; Walker CJ; et alii...

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. in The New England journal of medicine / N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27.

2023
AO Ordine Mauriziano

Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; et alii...